Assertio Holdings Inc Stock Price, News & Analysis

Assertio Holdings (NASDAQ: ASRT) announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Dan Peisert and CFO Paul Schwichtenberg will represent the company. An investor presentation is now available for on-demand viewing on the Assertio Investor Relations website for 30 days. Assertio focuses on commercializing differentiated pharmaceutical products in neurology, hospital care, and pain management. For more details, visit Assertio's website.

Assertio Holdings, Inc. (Nasdaq: ASRT) has announced the acquisition of Otrexup (methotrexate) from Antares Pharma for a total of $44 million, including $18 million paid upfront. This acquisition, the first since 2015, aims to enhance Assertio's growth and leverage its digital platform for commercialization. Assertio raised its full-year net product sales guidance to over $108 million and adjusted EBITDA to over $48 million for 2021, fueled by strong existing product sales and expected contributions from Otrexup.

Assertio Holdings, Inc. (ASRT) announced a preliminary settlement agreement regarding three shareholder derivative lawsuits against its subsidiary, Assertio Therapeutics, approved by the California Superior Court. The lawsuits, alleging breaches of fiduciary duties among other claims, will lead to corporate governance changes lasting at least two years. Assertio will also pay $150,000 in legal fees, subject to court approval. A settlement hearing is scheduled for December 14, 2021, to finalize the agreement and address any objections from current stockholders.

Assertio, a pharmaceutical company, reported Q3 2021 financial results, achieving net product sales of $25.997 million and a net income of $3.737 million. This marks a significant improvement from a net loss of $10.522 million in Q3 2020. The company raised its full-year net product sales guidance to over $103 million and adjusted EBITDA guidance to exceed $43 million. Sequentially, Assertio generated $4.7 million in operating cash flows, its highest since Q4 2019, while settling legal uncertainties, including a $7 million antitrust litigation settlement.

Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its third quarter 2021 financial results on November 4, 2021, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time on the same day. Stakeholders can join the call using the provided dial-in numbers: 1 (844) 200-6205 for domestic and 1 (929) 526-1599 for international participants. Assertio is known for its differentiated pharmaceutical products in the fields of neurology, hospital, and pain and inflammation.

Assertio Holdings, Inc. (NASDAQ: ASRT) announced investor presentations at several upcoming conferences. CEO Dan Peisert and CFO Paul Schwichtenberg will present at the LD Micro Main Event from October 12-14, 2021, the Stifel 2021 Virtual Healthcare Conference from November 15-17, and the Q4 Investor Summit from November 16-17. Additionally, they will participate in the Sidoti & Company Virtual Microcap Conference on December 8-9. Detailed information and live webcasts will be available on their investor website.

Assertio Holdings, Inc. reported net product sales of $24.8 million for Q2 2021, a significant increase from $20.2 million in Q2 2020. The company also raised its full year guidance for net product sales to $91-$96 million, up from $85-$92 million. Despite a net loss of $14.2 million in Q2, improved execution of cost-saving measures is expected to enhance adjusted EBITDA to between $34-$37 million. The company's transition to a non-personal promotional model has also contributed positively.

In addition, a legal reserve of $11.3 million was established, and the company regained compliance with NASDAQ after a reverse stock split.

Assertio Holdings (NASDAQ: ASRT) plans to release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call hosted by management will follow at 4:30 p.m. Eastern Time. Investors can access the live webcast and replay on the company's investor website. Assertio specializes in pharmaceutical products in neurology, hospital, and pain management. The company has achieved growth through licensing, mergers, and acquisitions.

Assertio Holdings, Inc. (ASRT) announced it has regained compliance with the Nasdaq's minimum bid price requirement, signaling a positive development for the company. The notification letter from Nasdaq confirms that the compliance issue is now resolved. Assertio continues to focus on its portfolio of branded prescription products in neurology, hospital, and pain management areas, driven by strategic growth through licensing and acquisitions.